Abstract
Schizophrenia is a chronic psychotic disorder defined by hallucinations, delusions, disorganized thought, and negative symptoms, indexed in the Medical Subject Headings vocabulary under the psychotic disorders. Its interest for cognitive psychology lies less in the florid psychotic symptoms than in a quieter finding: a broad, largely mood-independent impairment of attention, memory, processing speed, and executive control that predicts real-world functioning better than the psychosis itself. This article sets out the symptom dimensions, the cognitive profile and its measurement, the dopaminergic and neurodevelopmental neurobiology, the highly polygenic genetics, and treatment. Three interactive demonstrations model perceptual signal detection and hallucination-proneness, the aberrant-salience account of delusion formation, and the seven-domain cognitive profile that the field's consensus battery quantifies. Throughout, the disorder is treated as a disturbance of the cognitive systems that construct and test reality.
Keywords: psychosis, positive symptoms, negative symptoms, aberrant salience, cognitive impairment
Schizophrenia is distinguished from ordinary variation in belief and perception by the presence of psychosis — a loss of contact with consensual reality — sustained over time and accompanied by functional decline. A person in an acute episode may hear voices that no one else hears, hold unshakeable beliefs that are demonstrably false, and speak in a way whose logical thread is hard to follow, while family members note a withdrawal of drive, expression, and social engagement that began long before the first overt episode (Owen et al., 2016). The disorder affects roughly 1 in 300 people worldwide and typically emerges in late adolescence or early adulthood.
What makes schizophrenia a case for cognitive psychology rather than psychiatry alone is that its most disabling feature is not the psychosis but the cognition. Deficits in processing speed, attention, working memory, verbal learning, and executive control are present at the first episode, persist between episodes, and forecast whether a patient will work, live independently, and sustain relationships — more strongly than the severity of hallucinations or delusions does (Green, 1996; Nuechterlein et al., 2008). The psychotic symptoms are the visible surface; the cognitive impairment is the core that underlies much of the long-term disability.
Key Takeaways
- Schizophrenia is organized along symptom dimensions — positive (hallucinations, delusions), negative (blunted affect, avolition), disorganized, and cognitive — rather than into the classic subtypes, which recent diagnostic systems have abandoned.
- Cognitive impairment is present at the first episode and predicts functional outcome more strongly than psychotic symptoms do, making the disorder a fundamentally cognitive one.
- The dopamine hypothesis, refined to locate the abnormality in presynaptic striatal dopamine, is complemented by the aberrant-salience account, which explains how a dysregulated signal becomes a delusion.
- Heritability is high and the genetic architecture is highly polygenic; genome-wide studies now implicate hundreds of loci and converge on synaptic biology.
- The neurodevelopmental hypothesis frames schizophrenia as the late expression of an early disturbance in brain development, decades before the first psychotic episode.
What Schizophrenia Is
Schizophrenia is a severe, chronic psychotic disorder in which the machinery that constructs and tests reality malfunctions. Its symptoms are conventionally grouped into positive symptoms — additions to normal experience such as hallucinations (percepts without a corresponding external stimulus, most often voices) and delusions (fixed false beliefs held against contrary evidence); negative symptoms — subtractions from normal function such as blunted affect, poverty of speech, and avolition (loss of drive); disorganization of thought and behavior; and a pervasive cognitive impairment. A diagnosis requires that symptoms persist for a significant period and produce a marked decline in work, relationships, or self-care, distinguishing the disorder from brief or substance-induced psychosis.
The disorder is uncommon but not rare, with a lifetime prevalence near 0.3–0.7% and a strikingly consistent incidence across cultures (McCutcheon et al., 2020). Onset clusters in late adolescence and early adulthood, typically earlier and often more severe in men. A prodromal phase of attenuated symptoms, declining function, and subtle cognitive change frequently precedes the first psychotic episode by months or years. The course is variable: some people have a single episode with good recovery, but many face a chronic, relapsing illness in which negative and cognitive symptoms prove more persistent and more disabling than the positive symptoms that first bring them to attention (Owen et al., 2016). The Medical Subject Headings vocabulary indexes the condition among the psychotic disorders and preserves the historical entry term dementia praecox, the name under which it was first delineated.
Figure 1
The Symptom Dimensions of Schizophrenia
Types of Schizophrenia
Within the Medical Subject Headings vocabulary, Schizophrenia sits beneath the broader category of schizophrenia spectrum and other psychotic disorders and is subdivided into several narrower descriptors that correspond to the historical clinical subtypes. It is important to read this list correctly: MeSH is an indexing classification built to organize the literature, not a statement of current diagnostic practice. The subtype system it preserves was abandoned by DSM-5 (2013) and ICD-11 precisely because the subtypes proved unstable over time, overlapping, and poorly predictive of course or treatment — a patient classified as one subtype in one episode often met criteria for another in the next. Contemporary practice describes the illness along the symptom dimensions of Figure 1 instead. The narrower MeSH descriptors remain useful chiefly as index terms for the older literature.
| MeSH descriptor | Historical clinical picture |
|---|---|
| Catatonic schizophrenia | Dominated by psychomotor disturbance — immobility or stupor, mutism, rigidity, posturing, or excited purposeless movement. Catatonia is now recognized to occur across many disorders and is coded as a specifier rather than a subtype. |
| Disorganized schizophrenia | Marked by disorganized speech and behavior and flat or inappropriate affect, historically termed hebephrenia; typically early in onset and poor in prognosis. |
| Paranoid schizophrenia | Dominated by systematized delusions and auditory hallucinations, with relative preservation of cognition and affect; historically the most common and best-functioning presentation. |
| Treatment-resistant schizophrenia | Persistent symptoms despite adequate trials of two or more antipsychotics; a clinically vital category because it defines the indication for clozapine. A modern addition to the vocabulary, not a classical subtype. |
| Shared paranoid disorder | The transfer of a delusion from a person with psychosis to a close, previously well associate (historically folie à deux); a rare condition related to, but distinct from, schizophrenia proper. |
These subtypes are orthogonal to the dimensional view rather than alternatives to it: the same paranoid presentation, for instance, is described dimensionally by high positive and low negative scores. None currently has its own article on this site; each is glossed here from its MeSH scope so the reader can place the older terminology.
Symptom Dimensions
The modern description of schizophrenia replaces the subtypes with continuous dimensions, because factor-analytic work consistently recovers separable clusters of symptoms that vary independently within patients. The positive dimension captures hallucinations and delusions — experiences added to normal functioning — and it is the dimension most responsive to dopamine-blocking medication. The negative dimension captures what is lost: emotional expression, speech, motivation, and social drive. Negative symptoms are less dramatic but more corrosive, because they persist between episodes, resist treatment, and account for much of the disability that keeps people out of work.
A third dimension is disorganization — of thought, evident in derailed or tangential speech, and of behavior. A fourth, increasingly treated as central rather than secondary, is cognitive impairment. The reason the dimensional model won out is empirical: the dimensions dissociate. A person can have severe hallucinations with intact motivation, or profound negative symptoms with little active psychosis, and the two profiles predict different courses and respond to different treatments. The demonstration below models one route into the positive dimension — how a perceptual decision system set to a liberal threshold in noisy input begins to register signals that are not there.
Signal detection and hallucination-proneness
The listener must decide, on each trial, whether a faint voice is present in noise. The two curves are the internal evidence when only noise is present (left) and when a real signal is present (right). Move the decision criterion toward “liberal” or raise the sensory noise: the shaded area is the false-alarm rate — hearing a voice that is not there.
Sensitivity d′ = 1.70, bias c = 0.22. Hit rate 74%, false-alarm rate 14% — occasional false alarms.
Illustrative signal-detection model. A liberal criterion (negative c) and low sensitivity together raise false alarms, the perceptual analogue of hallucination-proneness; the account is a model of one route into the positive dimension, not a diagnostic test.
Cognition in Schizophrenia
The cognitive profile is the feature that most directly concerns cognitive psychology, and it has moved from the periphery of the disorder to its center. The impairment is broad rather than selective: patients perform roughly one to one-and-a-half standard deviations below matched controls across processing speed, attention and vigilance, working memory, verbal and visual learning, reasoning, and social cognition. The deficit is present at the first episode, is detectable in attenuated form during the prodrome, and — unlike the psychotic symptoms — does not remit with antipsychotic treatment.
Its clinical importance was established by the observation that neurocognitive performance predicts functional outcome — employment, independent living, social function — more strongly than symptom severity does (Green, 1996). This finding reoriented the field: if cognition, not psychosis, is the rate-limiting step for recovery, then cognition must be measured reliably and targeted directly. That motivated the MATRICS Consensus Cognitive Battery (MCCB), a standardized instrument covering seven cognitive domains, developed so that cognitive change could serve as a trial endpoint in the search for pro-cognitive treatments (Nuechterlein et al., 2008). Social cognition — the perception of others' emotions and intentions — emerged from this work as a domain in its own right, and one that mediates much of the relationship between basic neurocognition and real-world function (Green et al., 2015). The demonstration below reproduces the seven-domain profile and its composite.
The seven-domain cognitive profile (MCCB)
Each bar is a domain T-score (population mean 50, SD 10). The dashed line is the population mean; the solid line is the patient’s composite, the average across domains. Adjust any domain to see how the composite — and its distance below the mean — responds.
Composite T-score: 36.9 — about 1.3 SD below the mean, moderate impairment, typical of a first episode.
Illustrative. Because the composite averages across domains, improving one domain moves it only modestly — one reason pro-cognitive treatments have been hard to demonstrate on a global endpoint.
Neurobiology
The oldest neurochemical account is the dopamine hypothesis, prompted by the observation that all effective antipsychotics block D2 dopamine receptors and that dopamine-releasing drugs can induce psychosis. Its modern form is more precise: molecular imaging localizes the abnormality not to receptor density but to presynaptic dopamine — an excess of dopamine synthesis and release capacity in the associative striatum — reframing dopamine dysregulation as the “final common pathway” through which diverse risk factors produce psychosis (Howes & Kapur, 2009). Dopamine is not the whole story: a parallel glutamate hypothesis holds that hypofunction of NMDA-type glutamate receptors — the mechanism by which drugs such as ketamine reproduce positive, negative, and cognitive symptoms in healthy volunteers — sits upstream of the dopaminergic disturbance, and the two systems are increasingly modeled as one interacting circuit rather than as rival explanations (Howes et al., 2015). The aberrant salience hypothesis supplies the cognitive bridge from this chemistry to the experience of psychosis: dopamine normally tags events as motivationally significant, and when its firing becomes chaotic and stimulus-independent, neutral events acquire a spurious, compelling significance. Delusions, on this account, are the reasoning mind's attempt to explain the aberrant salience it cannot help but feel (Kapur, 2003). The demonstration below models this process.
Aberrant salience and the formation of delusions
Each row is a neutral everyday event with a small baseline salience. Raising the dopamine salience gain scales every event’s significance; bars that cross the threshold (dashed line) are tagged as meaningful. Watch how a raised gain turns ordinary events into a web of significance the mind must explain.
Events tagged as significant: 0 of 8. Events register as the ordinary background of the day; nothing demands explanation.
Illustrative model of Kapur’s aberrant-salience account. Baseline saliences are fixed; only the gain is under your control, isolating how dysregulated dopamine — not faulty logic — supplies the raw material a delusion is built to explain.
Genetics places schizophrenia among the most heritable psychiatric conditions, with twin-study heritability near 80%. The architecture is highly polygenic. A landmark genome-wide association study identified 108 loci, establishing that common variants of individually tiny effect, aggregated across the genome, carry much of the risk (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014). A far larger analysis has since extended this to 287 loci and, crucially, has begun to converge on biology — implicating genes concentrated in the neuron and especially the synapse, consistent with a disorder of synaptic function and connectivity (Trubetskoy et al., 2022). Running through the genetics and the imaging is the neurodevelopmental hypothesis: that schizophrenia originates in an early, possibly prenatal, disturbance of brain development whose consequences remain latent until the maturational changes of adolescence — synaptic pruning of prefrontal cortex among them — unmask a circuit that was subtly miswired from the start (Weinberger, 1987; Insel, 2010).
Measurement and Assessment
The standard instrument for rating symptom severity is the Positive and Negative Syndrome Scale (PANSS), a clinician-administered interview of 30 items covering a 7-item positive subscale, a 7-item negative subscale, and a 16-item general psychopathology subscale (Kay et al., 1987). Each item is rated from 1 (absent) to 7 (extreme), so the positive and negative subscales range from 7 to 49, the general subscale from 16 to 112, and the total from 30 to 210. The instrument's design reflects the dimensional structure of the disorder: by scoring the positive and negative syndromes on separate subscales rather than a single severity index, it allows the two to be tracked independently, which is essential given that they respond differently to treatment and predict different outcomes. The PANSS is the primary outcome measure in most antipsychotic trials, and the Worked Example below computes a case total. Cognitive severity is measured separately, by an instrument such as the MCCB, precisely because the cognitive dimension is not captured by symptom scales.
Table 1
Table 1
Principal Treatments for Schizophrenia
| Treatment | Role | Evidence |
|---|---|---|
| First-generation antipsychotics | Block D2 dopamine receptors; reduce positive symptoms | Effective for psychosis but carry a high burden of movement side effects |
| Second-generation antipsychotics | D2 blockade with broader receptor action; first-line for most patients | Similar efficacy for positive symptoms; metabolic rather than motor side effects |
| Clozapine | Reserved for treatment-resistant illness | Uniquely effective when two other agents have failed; requires blood monitoring |
| Psychosocial and cognitive interventions | Cognitive-behavioral therapy for psychosis, cognitive remediation, supported employment, family intervention | Evidence-based adjuncts targeting function, relapse, and residual symptoms |
Note. Medication reliably reduces positive symptoms but does little for the negative and cognitive dimensions that drive long-term disability; contemporary guidelines therefore combine pharmacological and psychosocial treatment, with early intervention emphasized (Jauhar et al., 2022).
Worked Example
Consider a patient assessed on the seven-domain MATRICS Consensus Cognitive Battery, whose scores are reported as normalized T-scores (population mean 50, standard deviation 10). Suppose the seven domains — speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition — are scored:
34, 38, 36, 32, 40, 42, 36
The illustrative composite is the mean of the seven domain T-scores. The sum is:
34 + 38 + 36 + 32 + 40 + 42 + 36 = 258
and the composite is:
258 ÷ 7 ≈ 36.9
A composite T-score of about 37 lies roughly 1.3 standard deviations below the population mean of 50 — the mean is 50 and each standard deviation is 10, so (50 − 36.9) ÷ 10 ≈ 1.3. This is squarely within the range typically observed at a first episode, and it illustrates the central point of the cognitive profile: the impairment is present across every domain, not confined to one, and it is large enough to matter for daily function even when it is not the patient's presenting complaint. Re-administering the battery after cognitive remediation is how change is quantified; because the composite averages across domains, an intervention that improves a single domain moves the composite only modestly, which is one reason pro-cognitive treatments have been hard to demonstrate.
Discussion
The most consequential shift in how schizophrenia is understood is the move from a psychosis-centered model to a cognition-centered one. For most of the twentieth century the hallucinations and delusions were the disorder, and treatment success was measured by their suppression. The discovery that neurocognitive impairment is present from the outset, persists through remission, and predicts functional outcome better than psychosis does relocated the core of the illness (Green, 1996; Nuechterlein et al., 2008). It also exposed a therapeutic gap: the medications that control positive symptoms leave the cognitive and negative dimensions largely untouched, which is why so many people whose psychosis is well managed remain unable to work.
The disorder also illustrates how a mechanistic hypothesis can knit biology to experience. The presynaptic dopamine finding and the aberrant-salience account together explain not just that dopamine matters but how a chemical dysregulation becomes the lived experience of a world grown menacingly meaningful (Howes & Kapur, 2009; Kapur, 2003). And the genetics has forced a reconsideration of diagnostic boundaries: the polygenic risk that genome-wide studies reveal is shared substantially with bipolar disorder and other conditions, suggesting that the categorical distinctions inherited from classical nosology cut across a more continuous underlying liability (Trubetskoy et al., 2022).
Cognitive Implications
Schizophrenia earns its place in cognitive psychology because it is, at its core, a disorder of the systems that build and check our model of reality. The positive symptoms can be read as failures of that checking: a perceptual system that reports signal where there is only noise, and a belief system that fails to reject hypotheses the evidence should overturn. The aberrant-salience account makes this explicit — delusions are not a failure of logic applied to good data but the reasonable output of logic applied to a corrupted salience signal (Kapur, 2003). The forward-model tradition offers a complementary reading of hallucinations, treating a voice as self-generated inner speech that the brain fails to tag as its own.
Beneath the psychosis lies the broader lesson: a disorder defined for a century by its most dramatic symptoms turns out to be carried, in terms of disability, by a quiet and pervasive impairment of the ordinary cognitive machinery — the speed, attention, memory, and control that cognitive psychology studies in the healthy mind (Green et al., 2015). That the same measures which characterize normal cognition also index the disorder's disability is what makes schizophrenia a subject for this discipline and not psychiatry alone.
Current Directions
Contemporary research is pursuing several fronts at once. The first is early intervention: because cognitive and functional decline begin in the prodrome, before frank psychosis, services increasingly aim to identify and treat people at clinical high risk, on the logic that intervening before the illness entrenches may alter its course (Jauhar et al., 2022). The second is the effort to convert the genetics into mechanism — the convergence of hundreds of risk loci onto synaptic genes has made synaptic function and connectivity, rather than any single neurotransmitter, the target of a new generation of mechanistic and therapeutic work (Trubetskoy et al., 2022). The third is the search for treatments that reach the cognitive and negative dimensions the dopamine-blocking drugs cannot: cognitive remediation, and pharmacological approaches acting on non-dopaminergic systems, an area where the first mechanistically novel antipsychotics in decades have recently emerged (McCutcheon et al., 2020). Across all three, the through-line is the reframing this article has traced: schizophrenia as a neurodevelopmental, fundamentally cognitive disorder of reality construction, not a disturbance of psychosis alone.
Common Misconceptions
- Schizophrenia means having a split personality.
- It does not. The word's Greek roots (a splitting of mental functions) refer to the disintegration of thought, emotion, and perception within a single mind, not to distinct personalities (Owen et al., 2016). The dissociation of identity into separate personalities is a different and unrelated condition.
- People with schizophrenia are typically violent and dangerous.
- The great majority are not; people with schizophrenia are far more likely to be victims of violence than perpetrators, and most of the modest elevation in risk is attributable to substance use rather than psychosis itself (McCutcheon et al., 2020). The stereotype is both inaccurate and stigmatizing.
- Once psychosis is treated, the person is well again.
- Antipsychotic medication reduces hallucinations and delusions but leaves the negative and cognitive symptoms largely untouched, and these are what most limit work and independence (Green, 1996). Remission of psychosis is not the same as recovery of function.
Glossary
- Aberrant salience.
- The assignment of undue motivational significance to neutral stimuli, attributed to dysregulated dopamine firing and proposed as the mechanism by which chemistry becomes delusion.
- Avolition.
- A negative symptom consisting of a marked reduction in the initiation and persistence of goal-directed activity.
- Delusion.
- A fixed false belief held with strong conviction and maintained against clear contradictory evidence, a core positive symptom.
- Disorganized symptoms.
- A symptom dimension comprising formal thought disorder, disorganized speech, and inappropriate or chaotic behavior, distinct from both positive and negative symptoms.
- Dopamine hypothesis.
- The proposal that psychotic symptoms arise from dysregulated dopamine transmission; in its modern form, from excess presynaptic dopamine synthesis and release in the associative striatum.
- Hallucination.
- A perception in the absence of a corresponding external stimulus; in schizophrenia most often auditory, typically voices.
- MATRICS Consensus Cognitive Battery.
- A standardized instrument measuring seven cognitive domains, developed to serve as a reliable endpoint for trials of pro-cognitive treatments in schizophrenia.
- Negative symptoms.
- Deficits representing a loss of normal function — blunted affect, poverty of speech, avolition, and social withdrawal — that resist treatment and drive much of the disability.
- Neurodevelopmental hypothesis.
- The view that schizophrenia originates in an early disturbance of brain development whose effects remain latent until unmasked by the maturational changes of adolescence.
- Positive and Negative Syndrome Scale.
- The standard 30-item clinician-rated instrument scoring positive, negative, and general symptom severity on separate subscales for a total of 30 to 210.
- Positive symptoms.
- Experiences added to normal functioning — hallucinations and delusions — that are the most responsive to dopamine-blocking medication.
- Prodrome.
- The phase of attenuated symptoms, declining function, and subtle cognitive change that often precedes the first psychotic episode.
- Psychosis.
- A loss of contact with consensual reality, marked chiefly by hallucinations and delusions; the defining but not the most disabling feature of schizophrenia.
- Social cognition.
- The perception and interpretation of others' emotions and intentions, a distinct cognitive domain that mediates the link between basic neurocognition and real-world function.
Key Researchers
Nancy Andreasen
(living). Professor of psychiatry at the University of Iowa; formalized the positive–negative symptom distinction and built the SANS and SAPS rating scales that shaped the modern description of the disorder. Wikipedia - Faculty Page
Eugen Bleuler
(1857–1939). Was a Swiss psychiatrist who coined the term schizophrenia in 1908 and identified its fundamental symptoms, replacing Kraepelin's more pessimistic concept of dementia praecox. Wikipedia - Wikidata
Chris Frith
(living). Emeritus professor at University College London; developed the influential forward-model account in which positive symptoms reflect a failure to recognize self-generated thoughts and actions as one's own. ORCID - Wikipedia
Michael F. Green
(living). Professor of psychiatry at the University of California, Los Angeles; established that neurocognition and social cognition are the strongest predictors of functional outcome and co-developed the MATRICS battery. Google Scholar - Faculty Page
Oliver Howes
(living). Professor at King's College London and Imperial College London; used molecular imaging to localize the dopamine abnormality to presynaptic striatal synthesis capacity and co-authored the dopamine hypothesis version III. ORCID - Google Scholar
Shitij Kapur
(living). Psychiatrist and neuroscientist; framed psychosis as a state of aberrant salience, supplying the cognitive bridge between dopamine dysregulation and the experience of delusion. ORCID - Wikipedia
Emil Kraepelin
(1856–1926). Was a German psychiatrist whose nosology delineated dementia praecox as a distinct deteriorating psychosis, the diagnostic ancestor of the modern concept of schizophrenia. Wikipedia - Wikidata
Robin Murray
(living). Professor at King's College London; central to the neurodevelopmental hypothesis and to the epidemiology of environmental risk factors such as cannabis, migration, and urban upbringing. Wikipedia - Google Scholar
Kurt Schneider
(1887–1967). Was a German psychiatrist who defined the first-rank symptoms of schizophrenia that anchored diagnostic criteria through the late twentieth century. Wikipedia - Wikidata
Frequently Asked Questions
What is schizophrenia?
Schizophrenia is a chronic psychotic disorder defined by hallucinations, delusions, disorganized thought, negative symptoms such as blunted affect and loss of drive, and a broad cognitive impairment (Owen et al., 2016). It typically emerges in late adolescence or early adulthood and affects roughly 1 in 300 people worldwide.
Does schizophrenia mean having a split personality?
No. The term refers to a fragmentation of thought, emotion, and perception within one mind, not to separate personalities (Owen et al., 2016). The splitting of identity into distinct personalities is a different, unrelated condition.
What are positive and negative symptoms?
Positive symptoms are experiences added to normal functioning, such as hallucinations and delusions, and respond best to medication; negative symptoms are losses of normal function, such as blunted affect and avolition, and are more persistent and disabling (Green, 1996). The two vary independently across patients.
Why is cognition so important in schizophrenia?
Cognitive impairment is present from the first episode and predicts employment, independent living, and social function more strongly than psychotic symptoms do (Green, 1996; Nuechterlein et al., 2008). This is why cognition, not psychosis, is often the limiting factor for recovery.
What causes schizophrenia?
It arises from a combination of high polygenic genetic risk and environmental factors acting on early brain development; genome-wide studies implicate hundreds of loci converging on synaptic biology (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014; Trubetskoy et al., 2022). The neurodevelopmental hypothesis frames it as the late expression of an early developmental disturbance.
What is the role of dopamine?
Effective antipsychotics block dopamine D2 receptors, and imaging shows excess presynaptic dopamine synthesis in the striatum, making dopamine dysregulation a final common pathway to psychosis (Howes & Kapur, 2009). The aberrant-salience account explains how that dysregulation becomes the experience of delusion (Kapur, 2003).
How is schizophrenia treated?
Antipsychotic medication is the mainstay for positive symptoms, with clozapine reserved for treatment-resistant illness, combined with psychosocial and cognitive interventions that target function and relapse (Jauhar et al., 2022). Medication does little for the negative and cognitive dimensions.
Can people with schizophrenia recover?
Outcomes vary widely: some people have a single episode with good recovery, while many face a chronic, relapsing course, and early intervention appears to improve the trajectory (McCutcheon et al., 2020). Recovery of function depends heavily on the cognitive and negative symptoms, not the psychosis alone.
Support Organizations
Organizations that provide information, treatment referral, and advocacy for schizophrenia and related psychotic disorders.
National Alliance on Mental Illness — education, support groups, and advocacy for people affected by serious mental illness. (United States)
Rethink Mental Illness — support and advocacy for people affected by severe mental illness, including schizophrenia. (United Kingdom)
National Institute of Mental Health — authoritative public-health information on symptoms, causes, and treatment. (United States)
References
Green, M. F. (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry, 153(3), 321-330. https://doi.org/10.1176/ajp.153.3.321
Green, M. F., Horan, W. P., & Lee, J. (2015). Social cognition in schizophrenia. Nature Reviews Neuroscience, 16(10), 620-631. https://doi.org/10.1038/nrn4005
Howes, O. D., & Kapur, S. (2009). The dopamine hypothesis of schizophrenia: Version III—the final common pathway. Schizophrenia Bulletin, 35(3), 549-562. https://doi.org/10.1093/schbul/sbp006
Howes, O., McCutcheon, R., & Stone, J. (2015). Glutamate and dopamine in schizophrenia: An update for the 21st century. Journal of Psychopharmacology, 29(2), 97-115. https://doi.org/10.1177/0269881114563634
Insel, T. R. (2010). Rethinking schizophrenia. Nature, 468(7321), 187-193. https://doi.org/10.1038/nature09552
Kapur, S. (2003). Psychosis as a state of aberrant salience: A framework linking biology, phenomenology, and pharmacology in schizophrenia. American Journal of Psychiatry, 160(1), 13-23. https://doi.org/10.1176/appi.ajp.160.1.13
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2), 261-276. https://doi.org/10.1093/schbul/13.2.261
McCutcheon, R. A., Reis Marques, T., & Howes, O. D. (2020). Schizophrenia—An overview. JAMA Psychiatry, 77(2), 201-210. https://doi.org/10.1001/jamapsychiatry.2019.3360
Nuechterlein, K. H., Green, M. F., Kern, R. S., Baade, L. E., Barch, D. M., Cohen, J. D., Essock, S., Fenton, W. S., Frese, F. J., Gold, J. M., Goldberg, T., Heaton, R. K., Keefe, R. S. E., Kraemer, H., Mesholam-Gately, R., Seidman, L. J., Stover, E., Weinberger, D. R., Young, A. S., ... Marder, S. R. (2008). The MATRICS Consensus Cognitive Battery, part 1: Test selection, reliability, and validity. American Journal of Psychiatry, 165(2), 203-213. https://doi.org/10.1176/appi.ajp.2007.07010042
Owen, M. J., Sawa, A., & Mortensen, P. B. (2016). Schizophrenia. The Lancet, 388(10039), 86-97. https://doi.org/10.1016/S0140-6736(15)01121-6
Schizophrenia Working Group of the Psychiatric Genomics Consortium. (2014). Biological insights from 108 schizophrenia-associated genetic loci. Nature, 511(7510), 421-427. https://doi.org/10.1038/nature13595
Trubetskoy, V., Pardiñas, A. F., Qi, T., Panagiotaropoulou, G., Awasthi, S., Bigdeli, T. B., Bryois, J., Chen, C.-Y., Dennison, C. A., Hall, L. S., Lam, M., Watanabe, K., Frei, O., Ge, T., Harwood, J. C., Koopmans, F., Magnusson, S., Richards, A. L., Sidorenko, J., ... van Os, J. (2022). Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature, 604(7906), 502-508. https://doi.org/10.1038/s41586-022-04434-5
Weinberger, D. R. (1987). Implications of normal brain development for the pathogenesis of schizophrenia. Archives of General Psychiatry, 44(7), 660-669. https://doi.org/10.1001/archpsyc.1987.01800190080012
Jauhar, S., Johnstone, M., & McKenna, P. J. (2022). Schizophrenia. The Lancet, 399(10323), 473-486. https://doi.org/10.1016/S0140-6736(21)01730-X